Dabrafenib Plus Trametinib Demonstrates Benefit in BRAF-Mutant Melanoma
Axel Hauschild, MD, PhD, discusses the key findings from the phase 3 COMBI-AD clinical trial, which demonstrated sustained long-term relapse-free survival benefit with the combination of dabrafenib and trametinib compared with placebo in patients with resected, stage III BRAF V600E/K-mutated melanoma.
Axel Hauschild, MD, PhD, a professor of dermatology at the University Hospital Schleswig-Holstein, in Campus Kiel, Germany, discusses the key findings from the phase 3 COMBI-AD clinical trial, which demonstrated sustained long-term relapse-free survival benefit with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) compared with placebo in patients with resected, stage III BRAF V600E/K-mutated melanoma.
In conclusion, we can say this is a highly effective treatment, says Hauschild. There is no doubt that for stage IIIA/B/C that this regimen will have benefit for patients.
One year of treatment with the combination of dabrafenib and trametinib is now considered the standard of care for this patient population, says Hauschild. This regimen is included in guidelines as the recommended treatment for patients with BRAF-mutant melanoma.
The overall survival data still need to be updated, but Hauschild says these findings are expected to be reported at some point within the next few years.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
